RAS MAPK Therapies And Expanding Trials Will Transform This Rare Cancer Specialist

AnalystHighTarget

Analyst High Target compiles bullish analysts opinions to create narratives which represent one standard deviation above the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls

Published

06 Jan 26

Updated

10 Aug 26

Views

Not Invested

Shared on 10 Aug 26

Fair value Decreased 10%

VSTM: TARGET-D Trials Will Shape Future Upside In Crowded KRAS Space

Wall Street cools a bit on Verastem as the race to treat certain cancer mutations gets more crowded, but some analysts still think the company can win if it proves its drug stands out. New trial starts and early results across multiple cancer types are now the big tests that could decide what happens next.

3 views

Fair Value vs Share Price

US$18

vs US$7.6157.7% undervalued

99.8%

Revenue growth

17.7%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Verastem

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Undervalued with slight risk.

Market capUS$653.9m

PB13.8x

Estimated Growth38.0%

Dividend YieldN/A

Full analysis

CEO & management

Daniel Paterson

CEO

2.7yrs

CEO Tenure

A development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.